BioLineRx (BLRX) Other Accumulated Expenses (2011 - 2025)

BioLineRx's Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $1.7 million for Q4 2025.

• On a quarterly basis, Other Accumulated Expenses fell 44.33% year-over-year to $1.7 million in Q4 2025; TTM through Dec 2025 was $1.7 million, a 44.33% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 44.33% from the prior year.
• Other Accumulated Expenses declined to $1.7 million in Q4 2025 per BLRX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.4 million in Q3 2024 and bottomed at $1.1 million in Q2 2021.
• The 5-year median for Other Accumulated Expenses is $1.9 million (2023), against an average of $2.0 million.
• Across the five-year window, Other Accumulated Expenses surged 99.65% in 2023 and sank 44.33% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.2 million in 2021, then soared by 42.14% to $1.7 million in 2022, then surged by 92.26% to $3.4 million in 2023, then dropped by 6.62% to $3.1 million in 2024, then sank by 44.33% to $1.7 million in 2025.
• Per Business Quant, the three latest BLRX Other Accumulated Expenses figures stand at $1.7 million (Q4 2025), $2.1 million (Q3 2025), and $2.8 million (Q2 2025).